Navigation Links
Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
Date:6/11/2008

GOTHENBURG, Sweden, June 11 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput platform, Dynaflow(R)HT, for ion channel screening.

Cellectricon and AstraZeneca formed and announced a collaboration in May 2006 aiming to find a solution to major bottlenecks in ligand gated ion channel screening. The results from this collaboration have successfully demonstrated the unique performance of Cellectricon's cell-based microfluidic screening platform. It has clearly demonstrated the opportunity to introduce the fully automated Dynaflow(R)HT System with unmatched level of stability and throughput while still delivering unique measurement data quality. The Dynaflow(R)HT System will be launched and commercially available in 2009.

"Collaborating with AstraZeneca has been most rewarding," says Jonas Ohlsson, CEO at Cellectricon. "Driven by solving bottlenecks in drug discovery, Cellectricon's strategy is to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations."

"This collaboration aims to accelerate our efforts in ion channel drug discovery and has been very fruitful to date. We look forward to working with the Dynaflow@HT Systems and see the impact of their throughput and cost effectiveness," says Dr. Jan-Erik Nystrom, VP Local Discovery Research Area CNS & Pain Control, Sodertalje, Sweden.

"The strength of this platform is that it is based on many years of cutting-edge academic and industrial research in ion channel drug discovery. I am happy to see us taking a new step together with a leading partner in advancing it further," says Dr. Jon Sinclair, VP Research & Development at Cellectricon.

About Cellectricon

Cellectricon AB (http://www.cellectricon.com), a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company will launch two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
5. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
6. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
7. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
9. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
10. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
11. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 2016 , ... Next week on May 5 at 2:55 ... for tissue stem cell counting and expansion to gene-editing scientists and other attendees ... Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing scientists appears ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and data ... to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” , ... of end users facing some of the most complex data challenges in the industry,” ...
(Date:4/27/2016)... NY (PRWEB) , ... April 27, 2016 , ... ... it. Touch screen mobile devices with fingerprint recognition for secure access, voice ... are only a few ways consumers are interacting with biometrics technology today. ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board ... the appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven ... the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
Breaking Biology Technology:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
Breaking Biology News(10 mins):